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Enterococci are a major cause of health care-associated infections and account for approximately 10% of all bacteremias glob-
ally. The aim of this study was to determine the proportion of enterococcal bacteremia isolates in Australia that are antimicro-
bial resistant, with particular emphasis on susceptibility to ampicillin and the glycopeptides, and to characterize the molecular
epidemiology of the Enterococcus faecalis and Enterococcus faecium isolates. From 1 January to 31 December 2011, 1,079 unique
episodes of bacteremia were investigated, of which 95.8% were caused by either E. faecalis (61.0%) or E. faecium (34.8%). The
majority of bacteremias were health care associated, and approximately one-third were polymicrobial. Ampicillin resistance was
detected in 90.4% of E. faecium isolates but was not detected in E. faecalis isolates. Vancomycin nonsusceptibility was reported
in 0.6% and 36.5% of E. faecalis and E. faecium isolates, respectively. Unlike Europe and the United States, where vancomycin
resistance in E. faecium is predominately due to the acquisition of the vanA operon, 98.4% of E. faecium isolates harboring van
genes carried the vanB operon, and 16.1% of the vanB E. faecium isolates had vancomycin MICs at or below the susceptible
breakpoint of the CLSI. Although molecular typing identified 126 E. faecalis pulsed-field gel electrophoresis pulsotypes,>50%
belonged to two pulsotypes that were isolated across Australia. E. faecium consisted of 73 pulsotypes from which 43 multilocus
sequence types were identified. Almost 90% of the E. faecium isolates were identified as CC17 clones, of which approximately
half were characterized as ST203, which was isolated Australia-wide. In conclusion, the Australian Enterococcal Sepsis Outcome
Programme (AESOP) study has shown that although they are polyclonal, enterococcal bacteremias in Australia are frequently
caused by ampicillin-resistant vanB E. faecium.
Enterococci, which were initially believed to be harmless inhab-itants of the gastrointestinal tract flora, have emerged as a ma-
jor cause of health care-associated infections (1). Globally, they
are now thought to account for approximately 10% of all bacter-
emias (2), and in North America and Europe are the fourth and
fifth leading cause of sepsis, respectively (3).
In the 1970s, health care-associated enterococcal infections
were associated with the introduction of third-generation cepha-
losporins and were primarily due to Enterococcus faecalis (4).
However, following the increased use of vancomycin and broad-
spectrum antibiotics, significant increases in the numbers of in-
fections caused by the more frequently resistant E. faecium were
reported in Europe and in North America (5, 6). Preceded by an
increase in infections and outbreaks caused by ampicillin-resis-
tant E. faecium, clinically significant isolates of vancomycin-resis-
tant enterococci (VRE) were subsequently detected in the United
Kingdom (7) and Europe (8) and shortly after in the United States
(9). By the early 1990s, VRE had become the second most com-
mon nosocomial pathogen in the United States (9) and was en-
demic in many North American hospitals (10). Vancomycin re-
sistance in E. faecium bacteremia isolates ranges from 5 to 35% in
Europe (see www.earss.rivm.nl) to 60% in North America (11).
The predominant VRE genotype in these two regions is vanA (12).
Although the origins of vanA in these settings are unclear, the past
use of the glycopeptide avoparcin as a growth promoter in animal
husbandry has been proposed as a contributing factor in Europe
(13).
In Australia, the first reported VREwas a vanA E. faecium from
a liver transplant recipient in 1995 (14). Since this time, however,
the vast majority of VRE have been E. faecium harboring the vanB
operon (15). Although prevalence or incidence rates of VRE in
Australian hospitals are not routinely collected, several reported
studies have shown a significant increase in the number of patients
infected or colonized with vanB E. faecium (16–18). In the 2010
Australian Group on Antimicrobial Resistance (AGAR) period
prevalence study of key resistances in clinical isolates of Enterococ-
cus species, vancomycin nonsusceptibility occurred in 36.5% of E.
faecium isolates, of which 98% were vanB VRE (see http://www
.agargroup.org/surveys).
In 2011, AGARcommenced theAustralian Enterococcal Sepsis
Outcome Programme (AESOP). In this study, we determined the
proportion of bacteremia isolates of Enterococcus species demon-
strating antimicrobial resistance, with particular emphasis on sus-
Received 22 November 2013 Returned for modification 19 December 2013
Accepted 27 December 2013
Published ahead of print 3 January 2014
Editor: W. M. Dunne, Jr.
Address correspondence to Geoffrey W. Coombs,
geoffrey.coombs@health.wa.gov.au.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.03286-13
March 2014 Volume 52 Number 3 Journal of Clinical Microbiology p. 897–905 jcm.asm.org 897
ceptibility to ampicillin and the glycopeptides and the molecular
epidemiology of E. faecalis and E. faecium.
MATERIALS AND METHODS
The Australian Group on Antimicrobial Resistance (AGAR) is a network
of laboratories located across Australia which provide microbiology ser-
vices to over 80% of the country’s tertiary acute care hospitals. AGAR has
been conducting national resistance surveillance for more than 25 years
(see http://www.agargroup.org), and for the last decade AGAR has been
funded by the Australian Department of Health.
Twenty-nine laboratories from all six states, the Australian Capital
Territory (ACT), and the Northern Territory (NT) participated in the
inaugural 2011 AGAR Australian Enterococcal Sepsis Outcome Program
(AESOP).
From 1 January to 31 December 2011, the 29 AGAR laboratories col-
lected all enterococcal species isolated from blood cultures. Enterococci
with the same species and antimicrobial susceptibility profiles isolated
from a patient’s blood culture within 14 days of the first positive blood
culture were excluded. A new enterococcal sepsis episode in the same
patient was recorded if it was confirmed by a further culture of blood
taken more than 14 days after the initial positive culture.
A web-based data entry system was constructed to enable the collec-
tion of real-time data into a common database. To ensure patient ano-
nymity, but to allow follow-up of discrepant results with each participat-
ing site, a record identifier unique to the participating laboratory was
used.
Each episode of bacteremia was designated health care associated if
any one of the following criteria applied (19, 20), (i) the first positive
blood culture(s) in an episode of infection were collected 48 h after
hospital admission, (ii) the patient resided in a nursing home or long-
term-care facility within the year preceding the positive blood culture(s),
(iii) the patient had a previous hospital admission for2 days within the
year preceding the positive blood culture(s), or (iv) the patient was receiv-
ing hemodialysis. If the patient did not meet the above criteria and the
blood culture was taken before or within 48 h of hospital admission, then
the episode was designated community associated (20).
Participating laboratories identified isolates to the species level by one
of the following methods: API 20S (bioMérieux), API ID32Strep (bio-
Mérieux), Vitek (bioMérieux), Phoenix (BD), Vitek-MS (bioMérieux),
matrix-assisted laser desorption ionization (MALDI) Biotyper (Bruker
Daltonics), PCR, or conventional biochemical tests.
Antimicrobial susceptibility testing at the contributing site was per-
formed according to each laboratory’s routine standardizedmethodology
(Clinical and Laboratory Standards [CLSI]-based disc diffusion, agar di-
lution, Vitek2, or Phoenix). Ampicillin and vancomycin susceptibilities
were tested by all laboratories. In addition 810 (75.1%) isolateswere tested
against linezolid and 991 (91.8%) and 258 (23.9%) screened for high-level
gentamicin and streptomycin resistance, respectively. For tests performed
by the participating institution, CLSI breakpoints were utilized for inter-
pretation (21). Isolates with an intermediate or resistant category were
classified as nonsusceptible.
Quality control was conducted as part of the routine laboratory prac-
tice in all 29 ISO 15189-accredited laboratories.
Of the isolates obtained from the 1,033 Enterococcus faecium and En-
terococcus faecalis sepsis episodes recorded by the participating laborato-
ries, 963 (93.2%) isolates were referred to the Australian Centre for En-
terococcus and Staphylococcus Species (ACCESS) Typing and Research for
further susceptibility testing and molecular typing. Vancomycin and tei-
coplanin MICs were performed by Etest (bioMérieux) according to the
manufacturer’s instructions. Linezolid MICs were performed by Etest
(bioMérieux) on linezolid-nonsusceptible isolates. Results were inter-
preted using both CLSI standards (21) and those of the European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) (version 3.1
[see http://www.eucast.org/clinical_breakpoints/]). Pulsed-field gel elec-
trophoresis (PFGE) of SmaI-digested DNA agarose plugs was performed
on all referred isolates as previously described (22). Banding patterns were
examined visually, scanned with a Quantity One device (Bio-Rad Labo-
ratories Pty, Ltd.), and digitally analyzed using FPQuest (Bio-Rad Labo-
ratories Pty., Ltd.). The Dice coefficient and the unweighted pair group
method with arithmetic mean were used with settings for tolerance and
optimization of 1.25% and 0.5%, respectively. Isolates with up to a six-
band difference were considered the same pulsotype (23). Multilocus se-
quence typing (MLST) was performed as previously described on a rep-
resentative isolate of each E. faecium PFGE pulsotype (24). If a PFGE
pulsotype included vancomycin nonsusceptible and vancomycin suscep-
tibleE. faecium,MLSTwas performedonboth phenotypes. The sequences
were submitted to http://www.mlst.net/, where an allele profile was gen-
erated and a sequence type (ST) assigned. Bu use of the eBURST V3
algorithm at the same website, STs were classified into eBURST groups
when amember of a group shared alleles at5 of the 7 loci. Double-locus
variants (dlvs) of an STwere includedwithin an eBURST group only if the
linking single-locus variant (slv) was present. The ancestral ST of an
eBURST group was defined as the ST that differed from the largest num-
ber of other STs at only a single locus (i.e., the ST that has the greatest
number of slvs). STs that diverged by nomore than twoof the sevenMLST
loci of the ancestral ST were considered to belong to the same clonal
complex (CC).
vanA and vanB PCRwas performed on the 963 referred E. faecium and
E. faecalis isolates either by the participating laboratory or by ACCESS
Typing and Research.
Regular audits for data discrepancies and potential duplicate entries
were conducted and resolved with each of the participating sites during
collection.
A chi-square test for comparison of two proportions was performed
and 95% confidence intervals were determined using MedCalc for Win-
dows, version 12.7 (MedCalc Software, Ostend, Belgium).
Approval to conduct the prospective data collection was given by the
research ethics committee associated with each participating laboratory.
RESULTS
From 1 January to 31 December 2013, 1,079 unique episodes of
enterococcal bacteremia were identified by the AGAR laborato-
TABLE 1 Enterococcus faecalis and Enterococcus faecium susceptibility results
Antimicrobial agent
E. faecalis E. faecium
No. tested No. (%) resistant (95% CI)a No. tested No. (%) resistant (95% CI)
Vancomycin 658 3 (0.5) (0.1–1.4)b 375 137 (36.5) (31.6–41.6)b
Ampicillin 658 0 375 339 (90.4) (87.0–93.2)
Linezolid 472 11 (2.3) (1.2–4.1)b 300 4 (1.3) (0.4–3.3)b
High-level gentamicin 607 211 (34.8) (31.0–38.7) 340 221 (65.0) (59.7–70.1)
High-level streptomycin 172 11 (6.4) (3.2–11.2) 79 18 (22.8) (14.1–33.69)
a As described in CLSI M100-A23 (21).
b Nonsusceptible.
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ries, of which 950 (88.0%) were health care associated (95% CI,
85.9 to 89.9%) and 359 (33.3%)were polymicrobial (95%CI, 30.5
to 36.2%). Twenty-eight patients had more than one episode.
Although eight species of Enterococcus were identified, 95.8%
were either E. faecalis (658 isolates, 61.0%) or E. faecium (375,
34.8%). Forty-five enterococci were identified either as Enterococ-
cus casseliflavus (15 isolates), E. gallinarum (14), E. avium (8), E.
raffinosus (4), E. durans (2), or E. hirae (2). One isolate could not
be identified to the species level.
Overall, 90.4% of E. faecium were ampicillin resistant (Table
1). Ampicillin resistance was not detected in E. faecalis. Vancomy-
cin nonsusceptibility (CLSI)was reported by the participating lab-
oratories in 0.6% and 36.5% of E. faecalis and E. faecium isolates,
respectively. Of the 137 vancomycin-nonsusceptible E. faecium
isolates, 133 (97.1%) were also ampicillin resistant. MICs were
performed on 14 of the 15 isolates reported as linezolid nonsus-
ceptible by the participating laboratory usingCLSI interpretations
(3 resistant and 11 intermediate). Eight isolates had MICs of 2
mg/liter (susceptible) and six isolates had MICs of 4 mg/liter (in-
termediate using CLSI interpretations and susceptible using
EUCAST interpretations). High-level gentamicin resistance was
reported by the participating laboratories in 65.0% of E. faecium
and 34.8% of E. faecalis isolates. In contrast, 22.8% of E. faecium
and 6.4% of E. faecalis isolates were high-level streptomycin resis-
tant.
Of the 963 isolates referred to the Australian Centre for Entero-
coccus and Staphylococcus Species (ACCESS) Typing and Re-
search, 622 (64.6%) were E. faecalis and 341 (35.4%) were E. fae-
cium.
Enterococcus faecalis. The vancomycin MICs for the 622 E.
faecalis isolates ranged from 0.25 to256mg/liter, with amode of
2 mg/liter (Fig. 1). The three vancomycin nonsusceptible isolates
(4mg/liter, 0.6%) harbored the vanB gene and had vancomycin
MICs of 16 mg/liter, 32 mg/liter, and256 mg/liter. No vanA or
vanB genes were detected in the vancomycin-susceptible isolates.
The teicoplanin MICs ranged from 0.064 to 2 mg/liter, with a
FIG 1 Enterococcus faecalis and Enterococcus faecium vancomycin MICs.
FIG 2 Enterococcus faecalis and Enterococcus faecium teicoplanin MICs.
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mode of 0.25 mg/liter (Fig. 2). The three vanB-containing isolates
had teicoplanin MICs of 0.125 mg/liter (two isolates) and 0.25
mg/liter (one isolate), i.e., below the susceptible CLSI and
EUCAST breakpoints.
By PFGE, 618 of the 622 E. faecalis isolates were classified into
126 pulsotypes, of which nine pulsotypes (Efs1 to Efs9) had 10 or
more isolates (Fig. 3). Four isolates could not be typed by PFGE.
Of the 117 pulsotypes that had 10 isolates, 66 pulsotypes were
represented by only one isolate. Geographically, the nine major
pulsotypes were widely distributed, with the two predominant
pulsotypes, Efs1 (191 isolates) and Efs2 (103 isolates), isolated
across Australia. The three van B E. faecalis isolates were detected
in pulsotype Efs2. Compared to non-Efs1/Efs2 bacteremia cases, a
significantly higher percentage of Efs1 and Efs2 bacteremia cases
were health care associated (80.8% versus 88.1%) (P 0.0171).
Enterococcus faecium. The vancomycin MICs for the 341 E.
faecium isolates ranged from 0.25 to256 mg/liter, with a mode
of 1.0mg/liter (Fig. 1). Of the 234 vancomycin-susceptible isolates
(MIC 4 mg/liter), 20 (8.5%) harbored the vanB gene and had
vancomycin MICs that ranged from 0.5 mg/liter to 4.0 mg/liter
(Fig. 4). Of the 107 vancomycin-nonsusceptible isolates (MIC4
mg/liter), two isolates harbored the vanA gene (vancomycin MIC
FIG 3 Distribution and proportion of Enterococcus faecalis (Efs) pulsotypes across Australia.
FIG 4 MICs of vanA-, vanB-, and vanA/B-negative Enterococcus faecium.
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256 mg/liter) and 104 harbored the vanB gene (vancomycin
MICs 6 to256 mg/liter) (Fig. 4). One isolate with a vancomycin
MIC of 6 mg/liter did not harbor vanA or vanB genes. The teico-
planin MICs ranged from 0.047 to256 mg/liter, with a mode of
0.5 mg/liter (Fig. 2). The two vanA isolates had teicoplanin MICs
of 32 and 64mg/liter.Of the 124 vanB isolates, onewas teicoplanin
intermediate (MIC 16 mg/liter) and three were resistant (MIC
16mg/liter) by CLSI criteria, and fivewere resistant by EUCAST
criteria (MIC2 mg/liter).
By PFGE, the 341 E. faecium isolates were classified into 73
pulsotypes from which 43 multilocus STs were identified (Table
2). Three of the seven housekeeping genes in PFGE pulsotype
Efm56 could not be amplified using the recommended MLST
primers and therefore a ST could not be assigned. By eBURST, 28
TABLE 2 Molecular epidemiology of health care- and community-associated Enterococcus faecium isolates


















1 17 203 15-1-1-1-1-20-1 Efm1 (77), Efm2 (48), Efm6 (15), Efm12 (4),
Efm14 (3), Efm15 (3), Efm16 (3), Efm17
(2), Efm35 (1), Efm41 (1), Efm50 (1),
Efm69 (1)
159 (46.6) 79 153 6
17 1-1-1-1-1-1-1 Efm5 (26), Efm9 (4), Efm10 (4), Efm11 (4),
Efm18 (2), Efm19 (2), Efm36 (1), Efm46
(1), Efm49 (1), Efm54 (1), Efm57 (1)
47 (13.8) 4 47
341 15-5-1-1-1-1-1 Efm3 (37), Efm32 (1) 38 (11.1) 1 33 38
555 4-1-1-1-1-1-1 Efm4 (34) 34 (10.0) 2 30 4
252 1-5-1-1-1-1-1 Efm7 (10), Efm38 (1) 11 (3.2) 1 11
80 9-1-1-1-12-1-1 Efm8 (5), Efm28 (1) 6 (1.8) 1 2 6
202 1-1-1-1-1-7-1 Efm48 (1) 1 (0.3) 1
117 9-1-1-1-1-1-1 Efm72 (1) 1 (0.3) 1
233 1-1-1-1-1-20-1 Efm37 (1) 1 (0.3) 1
UD 414 15-5-1-1-1-20-1 Efm23 (1), Efm64 (1) 2 (0.6) 2 1 1
UD 192 15-1-1-1-1-7-1 Efm24 (1) 1 (0.3) 1
UD 266 15-1-6-6-1-7-1 Efm20 (2) 2 (0.6) 2
UD 869 15-1-1-6-1-7-1 Efm55 (1) 1 (0.3) 1
2 22 22 2-3-1-2-1-1-1 Efm13 (3), Efm40 (1) 4 (1.2) 4
682 3-3-2-2-1-1-1 Efm29 (1) 1 (0.3) 1
533 2-3-1-14-1-1-1 Efm31 (1) 1 (0.3) 1
32 3-3-1-2-1-1-1 Efm63 (1) 1 (0.3) 1
21 9-3-1-2-1-1-1 Efm71 (1) 1 (0.3) 1
3 178 361 13-8-8-8-6-51-6 Efm26 (1) 1 (0.3) 1
94 13-8-8-8-6-10-6 Efm30 (1), Efm61 (1) 2 (0.6) 1 1
604 13-8-8-23-6-27-6 Efm60 (1) 1 (0.3) 1
60 13-8-8-8-11-10-6 Efm62 (1) 1 (0.3) 1
178 13-8-8-8-6-27-6 Efm67 (1) 1 (0.3) 1
4 UDb 18 7-1-1-1-5-1-1 Efm21 (1), Efm22 (1), Efm45 (1) 3 (0.9) 3
UD 273 7-3-1-1-5-7-1 Efm53 (1) 1 (0.3) 1
UD 262 7-1-1-1-5-7-1 Efm51 (1) 1 (0.3) 1
5 UD 674 25-8-14-22-10-73-6 Efm47 (1) 1 (0.3) 1
UD 648 25-8-14-22-10-71-6 Efm68 (1) 1 (0.3) 1
Sa S 19 7-1-1-1-1-11-1 Efm27 (1) 1 (0.3) 1
S S 54 2-9-6-6-1-11-1 Efm25 (1) 1 (0.3) 1
S S 264 5-4-6-6-2-1-8 Efm33 (1) 1 (0.3) 1
S S 870 25-8-14-22-10-19-11 Efm34 (1) 1 (0.3) 1
S S 583 5-18-14-22-8-26-6 Efm39 (1) 1 (0.3) 1
S S 867 3-7-3-73-1-1-1 Efm42 (1) 1 (0.3) 1
S S 639 2-40-12-3-1-1-1 Efm43 (1) 1 (0.3) 1
S S 798 5-13-18-17-8-19-6 Efm44 (1) 1 (0.3) 1
S S 868 4-5-1-6-1-92-1 Efm52 (1) 1 (0.3) 1
S S 863 4-59-1-1-1-20-1 Efm58 (1) 1 (0.3) 1 1
S S 47 9-2-1-11-1-14-5 Efm59 (1) 1 (0.3) 1
S S 873 5-4-1-3-1-1-5 Efm65 (1) 1 (0.3) 1
S S 871 36-21-9-17-10-59-6 Efm66 (1) 1 (0.3) 1
S S 875 15-1-1-22-1-20-6 Efm70 (1) 1 (0.3) 1
S S 866 13-8-58-72-6-27-6 Efm73 (1) 1 (0.3) 1
NTc Efm56 (1) 1 (0.3) 1
a UD, undefined.
b S, singleton.
c NT, nontypeable using recommended Enterococcus faecium MLST primers.
Enterococcal Bacteremia in Australia
March 2014 Volume 52 Number 3 jcm.asm.org 901
of the 43 STs were grouped into five eBURST groups (Fig. 5). The
remaining 15 STs were classified as singletons. eBURST group 1
consisted of 13 STs of which 9 STs formed clonal complex (CC)
17. The ancestral ST within CC17 was identified as ST17, from
which seven single-locus variants (slvs) and the double locus vari-
ant (dlv) ST203 were identified. ST203 was considered a co-
founder within eBURST group 1 from which an additional four
STswere linked.Overall, 38 pulsotypes were identified in eBURST
group 1, of which 12 and 11 pulsotypes were characterized as
ST203 and ST17, respectively. A further two CCs were character-
ized, including CC22 in eBURST group 2 and CC178 in eBURST
group 3. An ancestral ST was not identified in eBURST groups 4
and 5.
Overall, 304 (89.1%) E. faecium isolates were grouped into
eBURST group 1. Five STs, all found in CC17, had more than 10
isolates (Fig. 6). The twomajor STs, ST203 (159 isolates) and ST17
(47 isolates), were isolated across Australia. ST341 (38 isolates)
and ST252 (11 isolates) were isolated only in the eastern regions of
Australia, and ST555 (34 isolates) was isolated in the western and
central regions.
Apart from ST863 (pulsotype Efm58), isolates harboring a
vanA or vanB gene were located in eBURST group 1. However,
ST863, a ST203dlv, was not included in eBURST group 1 be-
cause no linking slv was identified. van genes were identified in
the five major STs and in ST80 and ST414. Although only 8.5%
(4/47) of ST17 isolates harbored vanB, vanB genes were iden-
tified in 50.6% (79/153) of ST203 isolates, including seven of
the 12 ST203 pulsotypes. All 48 of the ST203 Efm2 isolates were
vanB positive.
Overall, 94.4% of E. faecium isolates were health care associ-
ated. Compared to non-group 1 E. faecium bacteremia, a signifi-
cantly higher percentage of cases of group 1 E. faecium bacteremia
were health care associated, 78.4% versus 96.4% (P 0.0001).
DISCUSSION
Similar to the situation in the United States (25) and in Europe
(26), in Australia enterococcal bacteremia, and notably bacter-
emia caused by multidrug-resistant E. faecium, has become a sig-
nificant problem. In the AESOP 2011 study, approximately one in
three cases of enterococcal bacteremia was due to E. faecium, of
which 90.4% were ampicillin resistant and 36.5% were vancomy-
cin nonsusceptible. However, unlike Europe and the United
States, where vancomycin resistance in E. faecium is predomi-
nately due to the acquisition of the vanA operon, almost all E.
faecium blood culture isolates in Australia harboring van genes
carried the vanB operon (98.4%). Twenty (16.1%) of the 124 vanB
E. faecium isolates had vancomycin MICs at or below the CLSI
susceptible breakpoint (4 mg/liter) and would not have been
identified using routine phenotypic antimicrobial susceptibility
methods.
Similar to the study performed by Pinholt and colleagues in
Denmark (2), in our study the majority of bacteremia cases were
health care associated, and approximately one-third of episodes
were polymicrobial.
With the use of PFGE, both enterococcal species were shown to
be very polyclonal, confirming the enormous plasticity of the en-
terococcal genome, which has been demonstrated to acquire ge-
netic elements that can account for up to 25% of the genome (27).
FIG 5 eBURST-generated population snapshot of Enterococcus faecium sequence types (STs) isolated in the 2011 Australian Enterococcus Sepsis Outcome
Program (AESOP). Each ST is represented by a black dot. The numbers refer to a particular sequence type (ST). The size of each dot reflects the number of isolates
within a ST. The ancestral ST of a clonal complex is represented by a blue dot. The yellow-colored dot (ST203) is considered a subgroup cofounder.
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Although 126 E. faecalis PFGE pulsotypes were identified, 47.6%
of the isolates belonged to either Efs1 or Efs2. Isolated across Aus-
tralia, these two strains have had success in extending their geo-
graphical range, which may be due to the acquisition of mobile
genetic elements and single nucleotide polymorphisms that favor
spread and persistence. However, this hypothesis will need to be
confirmed by whole-genome sequencing. Both ampicillin and
vancomycin resistance in E. faecalis were uncommon. Only three
Efs2 isolates harbored van genes, and all were vanB.
The relative clinical importance of E. faecium bacteremia has
increased with the emergence of resistance to antimicrobials such
as ampicillin and vancomycin (28, 29). In at least one Australian
institution, VRE bacteremia has reportedly surpassedmethicillin-
resistant Staphylococcus aureus (MRSA) bacteremia (18). Glob-
ally, hospital-derived E. faecium isolates have been shown to be
part of a single clonal lineage, designated CC17 after its presumed
founder ST17, that has successfully adapted to hospital environ-
ments (30). CC17 is characteristically ampicillin and quinolone
resistant, and subsequent acquisition of vanA- or vanB-contain-
ing transposons by horizontal gene transfer in CC17 clones has
resulted in VRE with pandemic potential. In the AESOP 2011
study, the five major blood culture E faecium clones were all
grouped into CC17. In addition, seven of the eight clones harbor-
ing the vanA or vanB genes were also CC17 clones. The eighth
clone (ST863), although not a CC17 clone, was an ST203dlv.
ST203, a dlv of ST17, was first described in Australia in 2010 as
the cause of a sustained outbreak of vanB E. faecium bacteremia in
a hospital located on the eastern seaboard of Australia (18). Sub-
sequent to this report, ST203 has been identified as a major vanB
E. faecium clone in other Australian regions (31), Outside of Aus-
tralia, ST203 has also been reported in many Asian and European
countries (http://efaecium.mlst.net/), although isolates from
these countries almost always possess the vanA gene. In our study,
46.6% of E. faecium isolates were characterized as ST203, and
these were isolated Australia wide. Approximately 50% of ST203
isolates carried the vanB operon, while none harbored vanA genes.
Although 12 PFGE ST203 pulsotypes were identified, almost 80%
of isolates were classified as either pulsotype Efm1 or pulsotype
Efm2.Why some clones within CC17 dominate over other clones,
and why within a clone some pulsotypes dominate over other
pulsotypes, requires further genetic analysis.
ST17, the presumed founder of CC17, is thought to have suc-
cessfully adapted to the hospital environment by the cumulative
acquisition of resistance (ampicillin and vancomycin) and genes
(espEfm, hylEfm, and fms) that result in a putative selective advan-
tage (32). The acquisition of these genes has been followed by the
genetic diversification of ST17, resulting inmany slvs and dlvs that
presumably have acquired or lost genetic elements. This appears
to have facilitated clones in gaining further selective advantages in
hospital environments.
Importantly, the successful transmission of a genetically
adapted vancomycin-resistant E. faecium clone in a hospital may
not be attributable solely to suboptimal infection control prac-
tices. Recently, de novo generation of vancomycin-resistant vanB
E. faecium has been demonstrated to occur within patients, pre-
sumably occurring in the normal colonic flora by acquisition of
the vanB operon from anaerobic flora (33). The acquisition of a
selective advantage by a VRE clone not necessarily lead to the
long-term survival of that clone. In 2004, we described a large
single-strain outbreak of vanB E. faecium across several hospitals
in Western Australia (17). Characterized as CC17 ST173 (34),
once eradicated from the hospital environment this strain has not
subsequently been isolated in Western Australia, nor was it de-
tected in the AESOP 2011 bacteremia study. Furthermore, failure
FIG 6 Distribution and proportion of Enterococcus faecium (Efm) multilocus sequence types (ST) across Australia.
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to isolate ST173 during long-term follow-up screening of previ-
ously colonized patients suggests the strain no longer had a selec-
tive advantage once outside the hospital environment. Whole-
genome sequencing of isolates from the AESOP 2011 study will be
an important resource in our efforts to understand this species
and to develop novel infection control strategies to prevent the
emergence of this hospital superbug.
Our study had a number of limitations. Although achieving
national coverage, the participating laboratories service only ami-
nority of the Australian hospitalized population. Further, MIC
assays for vancomycin, teicoplanin, and linezolid were performed
by a commercial gradient diffusion method, and not the standard
reference broth microdilution method.
In conclusion, the AESOP 2011 study has shown that the ma-
jority of Australian enterococcal bacteremias are health care asso-
ciated, and though predominantly caused by E. faecalis, they are
frequently caused by ampicillin-resistant vanB E. faecium. Molec-
ular typing characterized over 50% of E. faecalis isolates as two
PFGE pulsotypes, and almost 90% of E. faecium isolates as CC17
clones, of which approximately half were ST203. Further studies
of the enterococcal genome will contribute to our understanding
of the evolution of enterococci in the hospital environment and
assist in preventing their nosocomial transmission.
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